scholarly journals Incidence of acute kidney disease after receiving hematopoietic stem cell transplantation: a single-center retrospective study

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6467 ◽  
Author(s):  
Akira Mima ◽  
Kousuke Tansho ◽  
Dai Nagahara ◽  
Kazuo Tsubaki
Keyword(s):  
Stem Cell ◽  
Kidney Disease ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Kidney Injury ◽  
Hematopoietic Stem ◽  
Hematological Disorders ◽  
Acute Kidney Disease

BackgroundPrevious reports have shown that acute kidney injury (AKI) is common after hematopoietic stem cell transplantation (HSCT), which is a crucial treatment for patients with hematological disorders. AKI could increase mortality and induce adverse effects including the development of chronic kidney disease. The incidence of AKI in association with HSCT reportedly varies significantly because several definitions of AKI have been adopted. Acute kidney disease (AKD) is a new concept that can clinically define both AKI and persistent decreases in glomerular filtration rate (GFR) state. We conducted a retrospective cohort study to determine the incidence of AKD after HSCT.MethodsThis study included 108 patients aged between 16 and 70 years undergoing HSCT. In this study, AKD included clinical condition of AKI or subacute decreases in GFR. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines based on serum creatinine. However, urine output data were not included to define AKI because the database lacked some of these data. Comparisons were made between groups using the Mann–Whitney U test.ResultsAcute kidney disease occurred in 17 patients (15.7%). There were significant differences between the AKD and non-AKD with respect to ABO-incompatible HSCT (p= 0.001) and incidence of acute graft versus host disease (GVHD) after HSCT (p< 0.001). The 100-day overall survival of patients with AKD and without AKD after HSCT was 70.6% and 79.8%, respectively (p= 0.409).DiscussionABO-incompatible HSCT and acute GVHD after HSCT were risk factors for the incidence of AKD. However, we could not find a significant association between AKD after HSCT and mortality.

scholarly journals The Development of Acute Kidney Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

2018 ◽  
Vol 51 (2) ◽  
pp. 136-144
Author(s):  
Nergiz Erkut ◽  
Nilay Ermantas ◽  
Hasan Mucait Ozbas ◽  
Sule Yuzbasıoglu ◽  
Sertac Cankaya ◽  
...  
Keyword(s):  
Stem Cell ◽  
Kidney Disease ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Acute Kidney Disease

Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review

2017 ◽  
Vol 21 (4) ◽  
pp. e12935 ◽  
Author(s):  
Rupesh Raina ◽  
Nicholas Herrera ◽  
Vinod Krishnappa ◽  
Sidharth Kumar Sethi ◽  
Akash Deep ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Kidney Injury ◽  
Hematopoietic Stem ◽  
Comprehensive Review

scholarly journals Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation

2019 ◽  
Vol 15 (2) ◽  
pp. 289-297 ◽  
Author(s):  
Amanda DeMauro Renaghan ◽  
Edgar A. Jaimes ◽  
Jolanta Malyszko ◽  
Mark A. Perazella ◽  
Ben Sprangers ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Thrombotic Microangiopathy ◽  
Kidney Injury ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Wide Range

Hematopoietic stem cell transplantation is a life-saving therapy for many patients with cancer, as well as patients with some nonmalignant hematologic disorders, such as aplastic anemia, sickle cell disease, and certain congenital immune deficiencies. Kidney injury directly associated with stem cell transplantation includes a wide range of structural and functional abnormalities, which may be vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial. AKI occurs commonly after stem cell transplant, affecting 10%–73% of patients. The cause is often multifactorial and can include sepsis, nephrotoxic medications, marrow infusion syndrome, hepatic sinusoidal obstruction syndrome, thrombotic microangiopathy, infections, and graft versus host disease. The risk of post-transplant kidney injury varies depending on patient characteristics, type of transplant (allogeneic versus autologous), and choice of chemotherapeutic conditioning regimen (myeloablative versus nonmyeloablative). Importantly, AKI is associated with substantial morbidity, including the need for KRT in approximately 5% of patients and the development of CKD in up to 60% of transplant recipients. AKI has been associated universally with higher all-cause and nonrelapse mortality regardless of transplant type, and studies have consistently shown extremely high (>80%) mortality rates in those patients requiring acute dialysis. Accordingly, prevention, early recognition, and prompt treatment of kidney injury are essential to improving kidney and patient outcomes after hematopoietic stem cell transplantation, and for realizing the full potential of this therapy.

scholarly journals Kidney Complications Due to Hematopoietic Stem Cell Transplantation-A Disorder of an Increasing Incidence?

2014 ◽  
Vol 12 (2) ◽  
pp. 90-96
Author(s):  
Lidija Orlic ◽  
Ivana Mikolasevic ◽  
Martina Pavletic-Persic ◽  
Ita Jelic ◽  
Sanja Raspor-Flajsman ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cell ◽  
Kidney Disease ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Chronic Kidney Failure ◽  
Secondary Malignancy ◽  
Hematopoietic Stem

AbstractHematopoietic stem cell transplantation (HSCT) is becoming an increasingly popular treatment considering that it is the only curative option for many malignant and non-malignant diseases. Many patients treated in this way have been followed for two or three decades post-transplant and are presumed to be cured. But, on the other hand, a great proportion of these patients are experiencing long-term side effects after HSCT, including non-malignant organ or tissue dysfunction, changes in quality of life, infections and secondary malignancy. Renal complications caused by HSCT are high and are associated with the development of both acute and chronic kidney failure. So, considering the increasing numbers of HSCT survivors many years after the transplantation, chronic kidney disease due to HSCT is becoming a growing problem and represents a new population of patients who are presented to nephrologists. The three most common forms of chronic kidney disease related to HSCT are: chronic calcineurin nephrotoxicity, glomerular disease after HSCT and HSCT associated thrombotic microangiopathy.

scholarly journals Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders

2015 ◽  
Vol 6 (3) ◽  
pp. 449-458 ◽  
Author(s):  
Hossam K. Mahmoud ◽  
Alaa M. Elhaddad ◽  
Omar A. Fahmy ◽  
Mohamed A. Samra ◽  
Raafat M. Abdelfattah ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Hematological Disorders
Sign in / Sign up

Export Citation Format

Share Document